About: Immunogenicity and Safety of an AS03-Adjuvanted H7N9 Pandemic Influenza Vaccine in a Randomized Trial in Healthy Adults

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Immunogenicity and Safety of an AS03-Adjuvanted H7N9 Pandemic Influenza Vaccine in a Randomized Trial in Healthy Adults Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Immunogenicity and Safety of an AS03-Adjuvanted H7N9 Pandemic Influenza Vaccine in a Randomized Trial in Healthy Adults
Creator	Li, Ping Innis, Bruce Schuind, Anne Segall, Nathan Ferguson, Murdo Frenette, Louise Friel, Damien Kroll, Robin Madan, Anuradha Soni, Jyoti
Source	PMC
abstract	Background. Almost 700 cases of human infection with avian influenza A/H7N9 have been reported since 2013. Pandemic preparedness strategies include H7N9 vaccine development. Methods. We evaluated an inactivated H7N9 vaccine in an observer-blind study in healthy adults aged 18–64 years. Participants (420) were randomized to receive 1 of 4 AS03-adjuvanted vaccines (low or medium dose of hemagglutinin with AS03(A) or AS03(B)), one nonadjuvanted vaccine, or placebo. The coprimary immunogenicity objective determined whether adjuvanted vaccines elicited an immune response against the vaccine-homologous virus, 21 days after the second vaccine dose per US and European licensure criteria in the per-protocol cohort (n = 389). Results. All adjuvanted vaccines met regulatory acceptance criteria. In groups receiving adjuvanted formulations, seroconversion rates were ≥85.7%, seroprotection rates ≥91.1%, and geometric mean titers ≥92.9% versus 23.2%, 28.6%, and 17.2 for the nonadjuvanted vaccine. The AS03 adjuvant enhanced immune response at antigen-sparing doses. Injection site pain occurred more frequently with adjuvanted vaccines (in ≤98.3% of vaccinees) than with the nonadjuvanted vaccine (40.7%) or placebo (20.0%). None of the 20 serious adverse events reported were related to vaccination. Conclusions. Two doses of AS03-adjuvanted H7N9 vaccine were well tolerated and induced a robust antibody response at antigen-sparing doses in healthy adults. Clinical Trials Registration. NCT01999842.
has issue date	2016-12-01(xsd:dateTime)
bibo:doi	10.1093/infdis/jiw414
bibo:pmid	27609809
has license	cc-by
sha1sum (hex)	a40c3d4523d6ffcbcb690d1507b3dfdebb3e8396
schema:url	https://doi.org/10.1093/infdis/jiw414
resource representing a document's title	Immunogenicity and Safety of an AS03-Adjuvanted H7N9 Pandemic Influenza Vaccine in a Randomized Trial in Healthy Adults
has PubMed Central identifier	PMC5144728
has PubMed identifier	27609809
schema:publication	J Infect Dis
resource representing a document's body	covid:a40c3d4523d6ffcbcb690d1507b3dfdebb3e8396#body_text
is schema:about of	named entity 'development' named entity 'Women' named entity 'Seattle' covid:arg/a40c3d4523d6ffcbcb690d1507b3dfdebb3e8396 named entity 'H7N9' named entity 'SAEs' named entity '21 days' named entity 'homologous' named entity 'H7N9' named entity 'World Health Organization' named entity 'seasonal influenza' named entity 'radial immunodiffusion' named entity 'vaccine' named entity 'SCRs' named entity 'H5N1 vaccines' named entity 'adjuvanted' named entity 'infection' named entity 'virus' named entity 'adjuvanted' named entity 'AS03' named entity 'vaccine' named entity 'H7N9' named entity 'cross-reactive' named entity 'AS03' named entity 'AS03' named entity 'AS03' named entity 'adjuvanted' named entity 'adjuvanted' named entity 'immune response' named entity 'adjuvanted' named entity 'institutional review boards' named entity 'antigen' named entity 'immune response' named entity 'gene' named entity 'placebo group' named entity 'headache' named entity 'Canada' named entity 'vaccine' named entity 'antibody' named entity 'AEs' named entity 'H7N7' named entity 'antibody' named entity 'immune response' named entity 'antigen' named entity 'vaccine' named entity 'adjuvanted' named entity 'adjuvanted' named entity 'RBCs' named entity 'vaccine' named entity 'vaccine' named entity 'MF59' named entity 'antilog' named entity 'viruses' named entity 'titer' named entity 'vaccine' named entity 'vaccine' named entity 'prime-boost' named entity 'influenza vaccine' named entity 'adjuvant' named entity 'infection' named entity 'placebo' named entity 'immune response' named entity 'gave birth' named entity 'adjuvanted' named entity 'autoimmune thyroiditis' named entity 'adjuvanted' named entity 'adjuvant' named entity 'H7N9' named entity 'reverse genetics' named entity 'vaccination' named entity 'influenza A virus' named entity 'virus'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software